^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    BRAF V600E + TERT mutation

    i
    Other names: BRAF, B-raf proto-oncogene, B-raf proto-oncogene, Serine/threonine kinase, V-Raf murine sarcoma viral oncogene homolog B, Serine/threonine-protein kinase B-Raf, Proto-oncogene B-Raf, BRAF1, RAFB1, B-raf proto-oncogene Serine/threonine-protein kinase, Murine sarcoma viral (V-Raf) oncogene homolog B1, B-raf serine/threonine-protein, 94 KDa B-raf protein, B-RAF1, TERT, Telomerase Reverse Transcriptase, Telomerase-Associated Protein 2, Telomerase Catalytic Subunit, HEST2, EST2, TCS1, TP2, TRT, PFBMF
    Entrez ID:
    673; 7015
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    Associations

    News

    Trials
    22d
    Genetic alterations and allele frequency of BRAF V600E and TERT mutation in papillary thyroid carcinoma with intermediate-to-high recurrence risk: a retrospective study. (PubMed, Clin Exp Med)
    Although genetic alterations in PTC can differ among different ethnicities, the AF of BRAF V600E and TERT mutations may be similar. The AF of BRAF V600E has the potential to be a novel indicator in predicting PTC invasiveness and prognosis.
    Retrospective data • Journal
    |
    BRAF (B-raf proto-oncogene) • TERT (Telomerase Reverse Transcriptase)
    |
    BRAF V600E • BRAF V600 • TERT mutation • TERT promoter mutation • BRAF V600E + TERT mutation
    12ms
    Transformation of Poorly Differentiated Papillary Thyroid Carcinoma to Anaplastic Thyroid Carcinoma, An Atypical Course! (ENDO 2023)
    Combination dabrafenib and trametinib were started. ATC prognosis is affected by many factors such as metastasis, age, treatment strategies, socioeconomic status and the presence of BRAF V600E and TERT mutations. Diagnosis can be challenging. Our patient presented months after his symptoms started and this is an atypical course of Anaplastic Thyroid Carcinoma as it usually progresses aggressively and rapidly.
    IO biomarker
    |
    BRAF (B-raf proto-oncogene) • TERT (Telomerase Reverse Transcriptase)
    |
    BRAF V600E • TERT mutation • BRAF V600E + TERT mutation
    |
    Mekinist (trametinib) • Tafinlar (dabrafenib)
    over1year
    A significance of concomitant BRAFV600E and TERT mutations in Polish patients with papillary thyroid microcarcinoma - a retrospective cohort study based on 430 cases. (PubMed, Thyroid)
    Regardless the molecular background of PTMC, the overall response to therapy is excellent, and long-term disease-free survival rates can be achieved by most patients.
    Retrospective data • Journal
    |
    TERT (Telomerase Reverse Transcriptase)
    |
    BRAF V600E • BRAF V600 • TERT mutation • BRAF V600E + TERT mutation